Cabozantinib is a multiple receptor tyrosine kinase inhibitor targeting MET (c‐MET), VEGFR2, RET, AXL, KIT and TIE‐2, which are implicated in tumor growth, metastasis and angiogenesis.6 This evidence concerns the gene KDR and neoplasm.